BrainGate Neural Interface for Tetraplegia (BG-Tablet-01 Trial)
Trial Summary
The BrainGate Neural Interface System is unique because it uses a small, implanted device in the brain to directly translate neural activity into control signals for assistive technologies, allowing people with tetraplegia to control devices like computers and tablets with their thoughts. This approach differs from other treatments as it provides a direct brain-computer interface, enabling more natural and precise control over technology without relying on muscle movement.
23578Research shows that the BrainGate Neural Interface System allows people with tetraplegia to control a tablet computer using their brain signals, demonstrating its potential to help paralyzed individuals interact with technology and improve their daily lives.
24568The BrainGate feasibility study, which is the largest and longest-running clinical trial of an implanted brain-computer interface, provides safety data for the BrainGate Neural Interface System. While the study focuses on people with paralysis, it offers valuable insights into the safety of chronically implanted microelectrode arrays in humans.
13467The trial does not specify if you need to stop taking your current medications, but it excludes those on chronic steroids or immunosuppressive therapy. It's best to discuss your specific medications with the trial team.
Eligibility Criteria
This trial is for individuals with severe paralysis due to conditions like brainstem stroke, ALS (Lou Gehrig's Disease), or spinal cord injuries leading to quadriplegia. Participants should be unable to move or speak but remain alert. Specific inclusion and exclusion criteria details are not provided.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Tetraplegia
- Spinal cord injury
- Brainstem stroke
- ALS